Statistical Tests And Outcomes - NAPLEX

1. A 58-year-old woman (weight 74 kg) with type 2 diabetes is considering adding Drug Y for cardiovascular risk reduction. In a clinical trial, major adverse cardiovascular events occurred in 8.0% of Drug Y patients vs 10.0% of placebo patients over 3 years; RR $=0.80$ (95% CI $0.70$ to $0.92$), $p=0.002$. Which statistical measure best supports the use of this medication for this patient?
   Answer: The 95% CI for RR (0.70 to 0.92), because it excludes 1 and supports a statistically significant risk reduction. This question evaluates understanding of statistical significance in cardiovascular risk reduction decisions. The critical statistical factor is the 95% confidence interval (0.70 to 0.92) which excludes 1, confirming statistical significance of the risk reduction. The correct answer (B) properly identifies that a confidence interval excluding 1 for relative risk demonstrates statistical significance, supporting the medication's efficacy. Option A incorrectly suggests the point estimate alone is sufficient without considering the confidence interval. Option C wrongly implies that statistical significance (p<0.05) automatically guarantees clinical meaningfulness for every patient, ignoring individual patient factors. Option D incorrectly dismisses a 20% relative risk reduction as clinically unimportant based solely on absolute difference. For evidence-based pharmacy practice, focus on confidence intervals as they provide both statistical significance (excluding null value) and precision of the estimate (width of interval), offering more complete information than p-values alone for clinical decision-making.
2. A 66-year-old man (weight 78 kg) with COPD is considering Vaccine V to prevent hospitalization from respiratory infection. In a randomized trial, hospitalization occurred in 4.5% with Vaccine V vs 6.0% with placebo; RR $=0.75$ (95% CI $0.58$ to $0.97$), $p=0.03$. Which statistical finding is most crucial for assessing drug efficacy?
   Answer: The RR of 0.75 with 95% CI excluding 1, supporting a statistically significant reduction in hospitalization risk. This question evaluates understanding of vaccine efficacy assessment using relative risk and confidence intervals. The key statistical finding is a relative risk of 0.75 with 95% confidence interval (0.58 to 0.97) excluding 1, demonstrating statistically significant reduction in hospitalization risk. The correct answer (A) appropriately identifies that the confidence interval excluding 1 confirms statistical significance of the 25% risk reduction. Option B incorrectly attributes effect size information to p-values, which only indicate significance probability. Option C illogically expects RR=0 for effectiveness, when any RR<1 indicates risk reduction. Option D inappropriately focuses on baseline risk alone without considering the treatment effect. For vaccine counseling in high-risk COPD patients, emphasize both the relative benefit (25% reduction) and absolute benefit (1.5% fewer hospitalizations), explaining that the confidence interval confirms this protection is real and not due to chance, supporting vaccination as an evidence-based preventive strategy.
3. A 40-year-old man (95 kg) with ulcerative colitis is considering an oral JAK inhibitor. In a maintenance trial, serious infection occurred in 3.2% with drug vs 1.8% with placebo (RR $=1.78$, 95% CI $1.01$ to $3.12$, $p=0.046$). What statistical data supports the risk vs. benefit analysis for this therapy?
   Answer: RR $=1.78$ with a 95% CI above 1.0 suggests a statistically significant increased risk of serious infection that should be weighed against benefit. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from maintenance trials is crucial for risk-benefit assessment of immunosuppressive therapies in ulcerative colitis. The key statistical factor influencing the decision is the relative risk of 1.78 with a 95% confidence interval excluding 1.0, indicating statistical significance for increased infection risk. The correct answer (A) best applies the statistical data by weighing the significant risk against benefits in counseling. Choice B dismisses the risk due to p-value proximity to 0.05, while choice C assumes low rates invalidate RR assessment. Choice D misstates that excluding 0 indicates no risk, confusing null values. A transferable skill is to incorporate harm estimates like RR into shared decision-making, considering patient risks. This framework promotes evidence-based practice by ensuring balanced evaluations of therapy safety and efficacy.
4. A 68-year-old woman (60 kg) with nonvalvular atrial fibrillation is evaluating apixaban vs warfarin. In a clinical trial, major bleeding occurred in 2.1%/year with apixaban vs 3.1%/year with warfarin (RR $=0.68$, 95% CI $0.55$ to $0.83$, $p<0.001$), while stroke/systemic embolism was also reduced. Which statistical measure best supports the use of this medication for lowering bleeding risk?
   Answer: The RR $=0.68$ with a 95% CI that excludes 1.0, indicating a statistically significant reduction in major bleeding. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is vital for evaluating anticoagulant options to minimize bleeding risk in patients with atrial fibrillation. The key statistical factor influencing the decision is the relative risk of 0.68 with a 95% confidence interval excluding 1.0, confirming statistical significance. The correct answer (A) best applies the statistical data by highlighting the significant reduction in major bleeding with apixaban, supporting its preference over warfarin in suitable patients. Choice B overemphasizes the p-value alone without regard to effect size, while choice C incorrectly identifies 0 as the null value for relative risk instead of 1.0. Choice D dismisses absolute rates despite their importance in assessing clinical relevance alongside statistical significance. A transferable skill is to evaluate both relative measures and absolute event rates when interpreting trial outcomes for risk-benefit analysis. This framework fosters evidence-based pharmacy practice by integrating statistical evidence with patient-specific factors to enhance safety and efficacy.
5. A 62-year-old man (92 kg) with type 2 diabetes and established ASCVD is considering adding empagliflozin to metformin. In a randomized trial of empagliflozin vs placebo added to standard care, the primary composite CV outcome occurred in 10.5% vs 12.1% of patients, respectively (RR $=0.87$, 95% CI $0.78$ to $0.98$, $p=0.02$). He asks whether the study results support using empagliflozin to reduce CV events for someone like him. How does the confidence interval impact your decision on patient treatment?
   Answer: The CI excludes 1.0, supporting a statistically significant reduction in CV events that can be considered in therapy selection. In pharmacy practice, applying statistical tests such as confidence intervals and p-values from clinical trials is essential for making evidence-based decisions on drug therapy for reducing cardiovascular risk in patients with type 2 diabetes and ASCVD. The key statistical factor influencing the decision is the 95% confidence interval around the relative risk, which excludes 1.0 and supports statistical significance. The correct answer (B) best applies the statistical data by recognizing that the CI excluding 1.0 indicates a significant reduction in CV events, supporting the use of empagliflozin in appropriate patients. Choice A misinterprets the CI as including 1.0 when it does not, leading to an incorrect conclusion of no benefit, while choice C wrongly assumes a narrow CI guarantees large clinical benefit without considering absolute rates. Choice D misapplies the CI by claiming it only addresses safety, ignoring its relevance to efficacy outcomes. A transferable skill for pharmacists is to always check if the confidence interval for relative risk excludes 1.0 to determine statistical significance, ensuring decisions balance efficacy, safety, and patient factors. This framework promotes evidence-based practice by integrating trial statistics with individualized care to optimize therapeutic outcomes.
6. A 60-year-old man (76 kg) with BPH is considering tadalafil daily vs tamsulosin. A trial reported dizziness in 6% with tamsulosin vs 3% with tadalafil (RR $=2.0$, 95% CI $1.10$ to $3.64$, $p=0.02$). What statistical data supports the risk vs. benefit analysis when counseling about adverse effects?
   Answer: RR $=2.0$ with a 95% CI above 1.0 indicates a statistically significant higher dizziness risk with tamsulosin. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is essential for adverse effect counseling in BPH treatments. The key statistical factor influencing the decision is the relative risk of 2.0 with a 95% confidence interval excluding 1.0, indicating statistical significance. The correct answer (A) best applies the statistical data by highlighting tamsulosin's higher dizziness risk, informing choices. Choice B dismisses RR based on low rates, while choice C misattributes higher risk to tadalafil. Choice D confuses requirement for CI crossing 0. A transferable framework is to use harm statistics for shared decision-making on tolerability. This enhances evidence-based practice by balancing efficacy and safety in urology counseling.
7. A 67-year-old man (weight 92 kg) with nonvalvular atrial fibrillation is being considered for Drug X to reduce ischemic stroke risk. In a randomized trial comparing Drug X vs placebo for 2 years, stroke occurred in 2.0% (20/1000) on Drug X vs 3.0% (30/1000) on placebo; relative risk (RR) $=0.67$ with 95% CI $0.38$ to $1.17$ and $p=0.15$. The patient asks whether the study proves Drug X lowers stroke risk. How does the confidence interval impact your decision on patient treatment?
   Answer: Because the 95% CI includes 1, the trial does not demonstrate a statistically significant reduction in stroke; routine use solely based on this trial is not supported. This question tests the application of confidence intervals in clinical decision-making for stroke prevention therapy. The key statistical factor is that the 95% confidence interval (0.38 to 1.17) includes 1, which means the study cannot rule out the possibility of no effect. The correct answer (A) appropriately recognizes that when a confidence interval for relative risk includes 1, the result is not statistically significant, regardless of the point estimate showing potential benefit (RR=0.67). Option B incorrectly ignores the confidence interval's importance in determining statistical significance. Option C misunderstands p-values, as p=0.15 > 0.05 indicates non-significance, not significance. Option D incorrectly states that confidence intervals for relative risk should cross 0, when in fact they should be evaluated against 1 for multiplicative measures. When interpreting clinical trials for patient care decisions, always evaluate both the point estimate and confidence interval together - if the CI includes the null value (1 for RR, 0 for absolute differences), the finding lacks statistical significance and additional evidence should guide treatment decisions.
8. A 52-year-old woman (66 kg) with rheumatoid arthritis is evaluating a biologic vs placebo for achieving ACR50 response at 24 weeks. A trial reports ACR50 in 38% vs 25% (OR $=1.84$, 95% CI $1.20$ to $2.82$, $p=0.005$). What conclusion can be drawn from the odds ratio provided in the study?
   Answer: Patients had higher odds of achieving ACR50 with the biologic, and the CI excluding 1.0 supports statistical significance. In pharmacy practice, applying statistical tests such as odds ratios and confidence intervals from clinical trials is vital for evaluating biologic therapies in rheumatoid arthritis to achieve response criteria. The key statistical factor influencing the decision is the odds ratio greater than 1 with a 95% confidence interval excluding 1.0, supporting increased likelihood of benefit. The correct answer (A) best applies the statistical data by concluding higher odds of ACR50 response, informing treatment recommendations. Choice B misinterprets OR >1 as reducing response, while choice C wrongly assumes OR reporting implies rarity and irrelevance. Choice D incorrectly states the CI includes 0, confusing the null value for OR which is 1.0. A transferable skill is to interpret odds ratios in context with event rates to distinguish statistical from clinical significance. This framework advances evidence-based pharmacy by facilitating personalized decisions based on robust trial interpretations.
9. A 36-year-old man (78 kg) with HIV is considering switching to a 2-drug regimen. In a switch trial, virologic suppression at 48 weeks was 93% with 2-drug therapy vs 94% with 3-drug therapy (RR $=0.99$, 95% CI $0.96$ to $1.02$, $p=0.40$). He asks if the 2-drug regimen is worse. What conclusion is most appropriate based on these statistics?
   Answer: The study did not show a statistically significant difference in suppression rates; the 2-drug regimen is not shown to be worse based on these data alone. In pharmacy practice, applying statistical tests such as relative risk and p-values from switch trials is essential for simplifying HIV regimens while maintaining efficacy. The key statistical factor influencing the decision is the 95% confidence interval including 1.0 and p-value >0.05, indicating no statistical significance. The correct answer (A) best applies the statistical data by concluding the 2-drug regimen is not shown worse, supporting switches if beneficial. Choice B misinterprets RR <1 as proof of inferiority, while choice C assumes p-value proves superiority. Choice D wrongly claims CI including 0 means significance. A transferable framework is to interpret non-inferiority in context with trial design and patient factors. This supports evidence-based decision-making by facilitating regimen optimization in HIV care.
10. A 66-year-old man (80 kg) with community-acquired pneumonia is being discharged and asks about shorter antibiotic courses. A trial comparing 5 days vs 7 days of therapy found clinical success in 90% vs 91% (RR $=0.99$, 95% CI $0.95$ to $1.03$, $p=0.62$). What is the clinical significance of the study's p-value in determining therapy duration?
    Answer: The p-value suggests no statistically significant difference in clinical success between durations; other factors (adherence, adverse effects) may guide selection. In pharmacy practice, applying statistical tests such as p-values and relative risks from clinical trials is essential for optimizing antibiotic duration in infections like pneumonia to promote stewardship. The key statistical factor influencing the decision is the p-value of 0.62, indicating no statistical significance in success rates. The correct answer (A) best applies the statistical data by noting no difference, allowing factors like adherence to influence duration choice. Choice B misreads p-value as proving superiority of shorter course, while choice C overstates non-significance as proof of equivalence. Choice D limits p-value to safety, ignoring efficacy. A transferable skill is to use non-significant results to explore practical advantages beyond statistics. This framework advances evidence-based practice by supporting judicious antibiotic use in outpatient settings.
11. A 70-year-old woman (63 kg) with insomnia is offered a new hypnotic. In a trial, next-day motor vehicle accidents occurred in 1.6% with the hypnotic vs 1.0% with placebo (OR $=1.62$, 95% CI $0.98$ to $2.68$, $p=0.06$). What statistical data supports the risk vs. benefit analysis for this therapy?
    Answer: The OR suggests a possible increased risk, but the CI includes 1.0 and $p>0.05$, so increased accident risk was not statistically confirmed. In pharmacy practice, applying statistical tests such as odds ratios and confidence intervals from clinical trials is vital for risk assessment of hypnotics in elderly patients. The key statistical factor influencing the decision is the 95% confidence interval including 1.0 and p-value >0.05, showing no statistical significance. The correct answer (A) best applies the statistical data by noting possible but unconfirmed increased accident risk, informing balanced counseling. Choice B overstates OR >1 as definitive proof, while choice C dismisses risk entirely based on p-value. Choice D misstates exclusion of 0 as required for increased risk. A transferable skill is to communicate statistical uncertainty in risk discussions, weighing against benefits. This framework enhances evidence-based practice by promoting safe prescribing for insomnia.
12. A 72-year-old man (weight 80 kg) with heart failure is evaluating Drug C vs Drug D for reducing hospitalizations. In a head-to-head trial, hospitalization occurred in 22% with Drug C vs 28% with Drug D over 1 year; RR $=0.79$ (95% CI $0.60$ to $1.04$), $p=0.09$. What is the clinical significance of the study's p-value in determining therapy?
    Answer: The $p$-value suggests the difference did not reach statistical significance at $\alpha=0.05$; other factors and totality of evidence should guide selection. This question examines interpretation of non-significant results in comparative effectiveness research for heart failure management. The crucial statistical element is that p=0.09 exceeds the conventional significance threshold of 0.05, and the confidence interval (0.60 to 1.04) includes 1. The correct answer (B) appropriately recognizes that the difference did not reach statistical significance, requiring consideration of other factors beyond this single study. Option A incorrectly interprets a non-significant p-value as proving superiority. Option C wrongly claims p>0.05 proves no difference exists, when it only indicates insufficient evidence to reject the null hypothesis. Option D misunderstands statistical significance thresholds, which are predetermined and not flexible based on proximity to 0.05. In pharmacy practice, non-significant results don't prove equivalence but indicate uncertainty; consider the totality of evidence including other studies, clinical guidelines, patient-specific factors, and the clinical importance of the observed difference when making therapeutic decisions.
13. A 73-year-old woman (68 kg) with osteoporosis is considering denosumab. In a trial, new vertebral fracture occurred in 2.3% with denosumab vs 7.2% with placebo over 3 years (RR $=0.32$, 95% CI $0.26$ to $0.41$, $p<0.001$). Which statistical finding is most crucial for assessing drug efficacy for fracture prevention?
    Answer: RR $=0.32$ with a 95% CI well below 1.0, indicating a statistically significant reduction in vertebral fractures. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is essential for selecting osteoporosis treatments to prevent fractures. The key statistical factor influencing the decision is the relative risk of 0.32 with a 95% confidence interval well below 1.0, demonstrating strong statistical significance. The correct answer (A) best applies the statistical data by highlighting denosumab's efficacy in reducing vertebral fractures, guiding recommendations. Choice B overstates p-value as guaranteeing universal benefit, while choice C confuses the null for RR as 0 instead of 1.0. Choice D ignores RR and CI, focusing only on placebo rates. A transferable framework is to combine relative risk reductions with absolute risks for clinical relevance assessment. This enhances evidence-based decision-making by optimizing fracture prevention strategies in pharmacy practice.
14. A 48-year-old man (84 kg) with epilepsy is considering switching from immediate-release (IR) to extended-release (ER) levetiracetam. In a study, seizure-free status at 6 months was 72% with ER vs 70% with IR (RR $=1.03$, 95% CI $0.94$ to $1.13$, $p=0.51$), while adherence improved with ER. What is the clinical significance of the study's p-value in determining therapy?
    Answer: The p-value suggests no statistically significant difference in seizure freedom; ER may still be reasonable if adherence benefits outweigh cost/coverage issues. In pharmacy practice, applying statistical tests such as p-values and relative risks from clinical studies is vital for formulation switches in epilepsy to improve adherence without compromising control. The key statistical factor influencing the decision is the p-value of 0.51, indicating no statistical significance in seizure freedom rates. The correct answer (A) best applies the statistical data by noting ER may be reasonable if adherence benefits justify, despite no superiority. Choice B misinterprets p-value as proving ER superiority, while choice C assumes non-significance means identical adherence. Choice D dismisses the study based on p-value. A transferable framework is to weigh non-significant efficacy against practical advantages like dosing convenience. This supports evidence-based decision-making by enhancing epilepsy management strategies.
15. A 45-year-old woman (weight 60 kg) is starting Antibiotic A for an uncomplicated infection and is concerned about developing antibiotic-associated diarrhea. In a cohort study, diarrhea occurred in 12% of patients receiving Antibiotic A vs 8% receiving Antibiotic B; RR $=1.50$ (95% CI $1.10$ to $2.05$), $p=0.01$. What statistical data supports the risk vs. benefit analysis for this therapy?
    Answer: RR $=1.50$ with a 95% CI that excludes 1, indicating a statistically significant increased risk of diarrhea with Antibiotic A. This question addresses interpreting adverse event data for antibiotic selection and patient counseling. The key statistical finding is a relative risk of 1.50 with a 95% confidence interval (1.10 to 2.05) that excludes 1, indicating a statistically significant 50% increased risk of diarrhea. The correct answer (A) accurately interprets this as a statistically significant increased risk that should be communicated during patient counseling. Option B incorrectly suggests RR values greater than 1 cannot be interpreted, when they clearly indicate increased risk. Option C misinterprets the p-value direction, as p=0.01 confirms higher (not lower) risk with Antibiotic A. Option D inappropriately dismisses statistical significance based on absolute difference alone, ignoring the confidence interval's clear exclusion of 1. When counseling patients about medication risks, translate relative risks into absolute terms they can understand (e.g., "12 out of 100 patients experience diarrhea with this antibiotic versus 8 out of 100 with the alternative") while acknowledging the statistical significance supports a true difference in risk profiles.
16. A 61-year-old man (86 kg) with hyperlipidemia is considering adding ezetimibe to a statin after an ACS event. A trial reported the primary endpoint occurred in 32.7% with statin+ezetimibe vs 34.7% with statin alone (RR $=0.94$, 95% CI $0.89$ to $0.99$, $p=0.016$). How does the confidence interval impact your decision on patient treatment?
    Answer: The CI excludes 1.0, indicating a statistically significant reduction that may support adding ezetimibe in high-risk patients. In pharmacy practice, applying statistical tests such as confidence intervals and p-values from clinical trials is crucial for add-on lipid therapies post-ACS to reduce cardiovascular events. The key statistical factor influencing the decision is the 95% confidence interval excluding 1.0, supporting statistical significance despite proximity to 1.0. The correct answer (A) best applies the statistical data by indicating ezetimibe's benefit in high-risk patients, guiding add-on use. Choice B dismisses significance due to CI closeness, while choice C prioritizes p-value over absolute reductions. Choice D confuses null for RR as 0 instead of 1.0. A transferable skill is to consider both statistical significance and magnitude of benefit in secondary prevention. This framework promotes evidence-based practice by optimizing lipid management strategies.
17. A 71-year-old man (74 kg) with heart failure with reduced ejection fraction is considering switching from enalapril to sacubitril/valsartan. In a trial, CV death occurred in 13.3% with sacubitril/valsartan vs 16.5% with enalapril (RR $=0.81$, 95% CI $0.73$ to $0.90$, $p<0.001$). Which statistical finding is most crucial for assessing drug efficacy in reducing CV death?
    Answer: The RR $=0.81$ with a 95% CI $0.73$ to $0.90$, which excludes 1.0 and indicates a statistically significant reduction. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from clinical trials is essential for selecting optimal therapies to reduce cardiovascular mortality in heart failure patients. The key statistical factor influencing the decision is the 95% confidence interval excluding 1.0 around the relative risk, indicating statistical significance. The correct answer (A) best applies the statistical data by emphasizing the significant reduction in CV death with sacubitril/valsartan, guiding therapy switches. Choice B undervalues the role of effect size and CI in favor of p-value alone, while choice C simplistically assumes RR not equal to 0 implies efficacy without statistical context. Choice D misstates the null value for RR as 0 instead of 1.0 for significance testing. A transferable framework is to prioritize confidence intervals for assessing precision and significance of relative measures in trial data. This approach supports evidence-based decision-making by integrating statistics with patient outcomes for improved heart failure management.
18. A 56-year-old man (88 kg) with gout is considering febuxostat vs allopurinol due to a prior rash with allopurinol. A safety trial reported CV death in 4.3% with febuxostat vs 3.2% with allopurinol (RR $=1.34$, 95% CI $1.03$ to $1.73$, $p=0.03$). What conclusion can be drawn from these results for counseling on CV risk?
    Answer: Febuxostat is associated with a statistically significant increased risk of CV death compared with allopurinol, since the CI excludes 1.0. In pharmacy practice, applying statistical tests such as relative risk and confidence intervals from safety trials is vital for counseling on cardiovascular risks of gout therapies. The key statistical factor influencing the decision is the 95% confidence interval excluding 1.0 around RR=1.34, confirming statistical significance for increased CV death. The correct answer (A) best applies the statistical data by noting febuxostat's higher risk compared to allopurinol, informing alternative selections. Choice B assumes small absolute differences negate significance, while choice C misinterprets p-value as indicating febuxostat's safety. Choice D wrongly states CI includes 0, confusing null values. A transferable skill is to interpret confidence intervals for harm outcomes to guide risk mitigation. This framework supports evidence-based practice by prioritizing patient safety in chronic disease management.
19. A 57-year-old woman (69 kg) with asthma is considering adding a LAMA inhaler. In a trial, severe exacerbation occurred in 12% with LAMA add-on vs 15% with placebo add-on (RR $=0.80$, 95% CI $0.64$ to $0.99$, $p=0.045$). How does the confidence interval impact your decision on patient treatment?
    Answer: Because the CI barely excludes 1.0, the reduction is statistically significant and may support add-on therapy while considering patient-specific factors. In pharmacy practice, applying statistical tests such as confidence intervals and p-values from clinical trials is crucial for add-on inhaler therapies in asthma to reduce exacerbations. The key statistical factor influencing the decision is the 95% confidence interval barely excluding 1.0, supporting statistical significance. The correct answer (A) best applies the statistical data by indicating potential benefit of LAMA add-on, considering patient factors. Choice B dismisses significance due to CI proximity, while choice C overstates p-value as eliminating exacerbations. Choice D misstates exclusion of 0 as required. A transferable skill is to evaluate borderline significance in context with clinical relevance. This framework promotes evidence-based practice by refining asthma control approaches.
20. A 28-year-old woman (weight 62 kg) with migraine is considering Preventive Drug H. In a trial, the mean reduction in monthly migraine days was 2.1 days with Drug H vs 1.4 days with placebo; mean difference $=0.7$ days with 95% CI $0.1$ to $1.3$, $p=0.02$. How does the confidence interval impact your decision on patient treatment?
    Answer: Because the 95% CI does not include 0, the reduction is statistically significant; discuss whether a 0.7-day average benefit is clinically worthwhile for her. This question tests interpretation of mean differences and confidence intervals for continuous outcomes in migraine prevention. The critical statistical element is that the 95% confidence interval (0.1 to 1.3 days) excludes 0, confirming statistical significance of the 0.7-day reduction. The correct answer (A) properly recognizes statistical significance while appropriately questioning clinical significance of a modest benefit. Option B misunderstands confidence intervals for mean differences, which should exclude 0 (not include positive values) for significance. Option C incorrectly extrapolates from p-values to guarantee specific benefit magnitudes. Option D completely misinterprets the confidence interval, as values represent migraine day reductions, not increases. In pharmacy practice, distinguish between statistical significance (CI excludes null) and clinical significance (meaningful benefit to patient) - a 0.7-day average reduction may be worthwhile for some patients but not others, requiring shared decision-making about whether the benefit justifies treatment burden and cost.

Start this quiz